Plant patentability and the European Patent Office – what is the latest update?

Plant patentability has long been a contentious issue throughout intellectual property and scientific circles. The question as to whether plants or animals created through essentially biological processes, such as genetic or selective breeding, can be...

The SPC manufacturing waiver: curtailing protection or boosting competition?

Lucy O’Brien, Trainee Patent Attorney, A. A. Thornton & Co. Supplementary Protection Certificates (SPCs) are a valuable IP asset to most major life science businesses. The ability to extend the term of a patent relating to a...

Creating a Corona Vaccine

Varuni Paranavitane, IP Solicitor,  AA Thornton. As the world faces unprecedented challenges caused by the SARS-Cov-2 virus, we look at the science behind vaccine technology being investigated and how intellectual property rights may play a part...

How intellectual property can help 3D printing support, not harm, medtech

3D printing, or additive manufacturing, is frequently, and rightly, hailed as the next revolution in technology. Since its inception in 1986, 3D printing has transformed numerous sectors including aviation, manufacturing, and energy, and altered perceptions...

Is your IP Strategy fit for purpose? – Five Questions to Ask Yourself

As a result of the lockdown due to the global pandemic there is a greater need and renewed focus on using innovation to kick-start the economic recovery. The result is significant investment in R&D...

How to protect your IP rights in Europe

Intellectual property rights are territorial rights, meaning that the protection afforded by a granted patent or a registered trademark is geographically limited. Many companies that protect their inventions, brands or product designs in their home...

Considering a pharma and bioscience patent? The UK Intellectual Property Office maps out the...

Lawrence Cullen & Laura Starrs, Patent Examining Group Heads, IPO Managing a patent portfolio requires, among many skills, the ability to anticipate the future. This is especially true in the fields of bioscience and pharma where,...

Why is Diligent Due Diligence Important?

Alex Bone, Patent Attorney, Partner,  AA Thornton. Background Biopharma merger and acquisition activity was lower in 2021 than in recent years, but the top 10 deals still reached a combined value of over $50 billion. The main...

Preparations for AI patenting in Europe

The current era of rapid technological development requires industry to be quick to respond to challenges and opportunities, with many choosing to exploit new AI technologies rather than wait to be disrupted by competitors. Intellectual...

Protecting Digital Medtech Innovation

For many years the medical technology (medtech) sector has been at the forefront of innovation and the Covid-19 pandemic has not slowed it down, with new technology quickly being developed to test for, prevent...

Patenting aerospace medicines – the final frontier?

Research and development (R&D) into aerospace medicine can be viewed as falling into one of two camps: that aimed at adapting an existing ‘terrestrial’ medicine for use in the aerospace environment; and that which...

Is your Invention Plausible?

Alex Bone, Patent Attorney, Partner,  AA Thornton The market exclusivity provided by a patent can be crucial for allowing a company to obtain a return on their R&D investment. A patent is essentially a deal in which,...

UK offers accelerated patent protection for eco-friendly innovations

Using the Green Channel to accelerate a UK patent application. AdamsonJones was able to obtain patent protection for client, LLEO Ltd, in just 15 months from the moment the Green Channel was used. This acceleration was crucial as...

Are your innovations protected?

Innovation is something that defines the biosciences sector. The UK biotechnology and medical industries are among some of the most progressive in the world with billions invested annually on creating industry-leading drugs, techniques, therapies, and...

Biosimilars and Patents

Leonita Paulraj - Associate, AA Thornton The majority of the world’s biggest selling medicines can be classified as “biologics” or “biopharmaceuticals”. Such medicines contain one or more biologically active product produced from (or containing components of)...

Drug delivery

Dr Jason Bellia, Senior Patent Examiner at the UK Intellectual Property Office (IPO) I will look at just two of a vast number of routes - one to deliver nucleic acids across cell membranes and another looking...